Preventive cardiologyPhenotypic Predictors of Response to Simvastatin Therapy Among African-Americans and Caucasians: The Cholesterol and Pharmacogenetics (CAP) Study
Section snippets
Study population
Between March 2002 and October 2004, we enrolled 1,007 African-American and white men and women, aged ≥30 years, with a baseline total serum cholesterol level of 160 to 400 mg/dl in the PARC Study. Using clinic-based flyers, public service advertisements, and community outreach, we recruited and enrolled participants at 2 clinical centers located at San Francisco General Hospital (San Francisco, California) and from the University of California, Los Angeles, School of Medicine (Los Angeles,
Results
The baseline characteristics of the CAP participants are presented in Table 1. On average, we enrolled middle-age African-American and white men and women who were overweight or obese and had high blood pressure (Table 1). The African-American and white participants differed in a number of demographic and medical variables. Compared with the African-Americans, the whites were more likely to be married, more educated, and leaner, and were less likely to have high blood pressure or be current
Discussion
Most studies of the effects of statins have reported that the beneficial effect of statins on clinical outcomes, such as coronary heart disease events, occurs across all subgroups. Relatively few studies have examined whether statins affect lipid and lipoprotein levels differentially when stratified by demographic and phenotypic characteristics. The Expanded Clinical Evaluation of Lovastatin (EXCEL) study reported on the differential effects of lovastatin by patient characteristics.3 In the
Acknowledgment
Simvastatin was donated by Merck and Company, Incorporated, Horsham, Pennsylvania.
References (11)
- et al.
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Clin Chem
(1972) Statistical analysis system, version 8.02
(2001)- et al.
Expanded Clinical Evaluation of Lovastatin (EXCEL) study resultseffect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins
Circulation
(1992) - et al.
Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary disease are equal to or exceed those seen in younger patientsresults from the LIPID trial
Ann Intern Med
(2001) - et al.
Efficacy and tolerability of lovastatin in a six-month studyanalysis by gender, age and hypertensive status
Am J Cardiol
(1990)
Cited by (172)
A gene–diet interaction controlling relative intake of dietary carbohydrates and fats
2022, Molecular MetabolismCitation Excerpt :In a preliminary study, we examined whether the use of statins may affect plasma AGRP levels in a cohort of human subjects. In 79 individuals in the Cholesterol and Pharmacogenetics (CAP) clinical trial treated with 40 mg/d simvastatin for 6 weeks [44], there was a small but significant reduction of AGRP levels (paired t-test: 66.5 vs. 63.5 pg/mL, p = 0.004). Body weights were not significantly altered by statin treatment.
Association Between Age and Low-Density Lipoprotein Cholesterol Response to Statins
2023, Annals of Internal MedicineLong-term change in the target achievement rate of low-density lipoprotein cholesterol in patients with cardiovascular disease
2023, International Journal of Clinical Pharmacology and Therapeutics
CAP was supported by Grant U01-HL69757 from the National Institutes of Health, Bethesda, Maryland. Additional support was provided by Pfizer, Incorporated, New York, New York.